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Abstract. Background/Aim: Triple-negative breast cancer
(TNBC) can be divided into subtypes of basal-like (BL),
mesenchymal-like (ML), luminal androgen receptor (LAR), and
immunomodulatory (IM). The aim of our study was to assess
whether there are distinct radiologic features within the
different TNBC subtypes and whether this has potential clinical
impact. Patients and Methods: Imaging pictures of 135 patients
with TNBC were re-evaluated. TNBC subtyping was performed
on asservated tumor tissue using a panel of antibodies. Results:
Mammographic margins of LAR-TNBC were more often
spiculated (24.3% versus 0-4.1%). BL-TNBC presented more
frequent a mass without calcification in mammogram than
other subtypes (71.4% versus 48.6-57.9%). In ultrasound, ML
and LAR were described more often with smooth borders.
Conclusion: The histopathological subtype of TNBC influences
its presentation in ultrasound and mammogram. This can
reflect a different growth pattern of the subtypes and may have
an impact on the early diagnosis of TNBC.
Molecular typing led to a vast improvement in the diagnosis
and treatment of breast cancer (BC) decades ago. Targeted
therapy was developed for cancers with hormonal receptor
positivity and for HER2 positivity, which significantly
improved their prognosis. Lacking the three markers of
estrogen receptor (ER), progesterone receptor (PR), and HER2
receptor, triple negative breast cancer (TNBC) remains the
most feared diagnosis with poor outcomes (1). TNBC is
associated with younger age and a higher tumor stage at
diagnosis, as well as BRCA 1 germline mutation (2). Today,
TNBC is regarded as a heterogeneous disease. Subtyping
provides further information about the molecular pathways,
chemotherapy response, and the potential for development of
targeted therapies (3). The TNBC subtypes have been classified
into basal-like (BL), mesenchymal-like (ML), and luminal
androgen receptor (LAR); lymphocytic infiltration defines a
further subtype of immunomodulatory (IM) TNBC (3-5). 
Early detection is crucial for the curative treatment of BC,
especially for aggressive tumors. Mammography is considered
to be the gold standard for screening of BC. In cases of dense
breast tissue, family history of BC, and in women with
suspicious findings in mammogram or clinical examination,
additional ultrasound is indicated. For the objective assessment
of breast lesions, the Breast Imaging Reporting and Data
System (BI-RADS) has been established (6). Several features
of mammographic and sonographic breast findings are
evaluated algorithmically to minimize radiologist-dependent
subjective ratings. TNBC is known to present more often
benign characteristics in clinical imaging such as lobulated,
oval-shaped, and circumscribed margins, than other types of BC
(7). Benign classification and misinterpretation can lead to
diagnostic delay and negative impact on the outcomes of BC
(8). Despite TNBC subtypes having different therapy responses
and outcomes, very little is known about their characteristics in
clinical imaging. In this study we assessed specific features of
TNBC subtypes in mammogram and ultrasound with the aim
of improving the understanding of this heterogeneous disease.
Patients and Methods
Patients with TNBC who were diagnosed in the Breast-Center Zurich
between 2002 and 2016 were included in the study. Patient- and
disease-related data as well as outcome were evaluated retrospectively. 
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At patient’s first presentation, initial evaluation had been performed
and documented by trained breast radiologists in the Breast-Center
Zurich. Standardized mammogram had been performed in two imaging
planes (mediolateral oblique and craniocaudal). Ultrasound with 5-12
MHz transducers had been performed according to the BI-RADS
guidelines. For classification reassessment, mammogram and
ultrasound pictures were retrospectively reviewed by two experienced
breast radiologists who were blinded for the patient’s history and
histopathological subtyping of the tumor. Radiological tumor
characteristics such as margin, shape, orientation, echo pattern, and
posterior features were categorized according to the BI-RADS
classification. To analyse potential factors for misdiagnosis, the initially
given BI-RADS classification (benign/probably benign versus probably
malignant) was not changed but correlated to imaging features.
At initial diagnosis, surgical and biopsy specimens had been
processed as formalin-fixed, paraffin-embedded tumor tissues
according to the standardized protocol of the Department of
Pathology and Molecular Pathology, University Hospital Zurich,
Switzerland. TNBC had been defined as expressing less than 1% of
ER and PR by immunohistochemistry and being negative for HER2
expression. A tissue micro array (TMA) was constructed from the
asservated surgical specimen according to Kündig et al. as described
previously (9, 10). TNBC subtyping into Basel-like (BL),
Immunomodulatory (IM), Mesenchymal-like (ML), and Luminal
androgen receptor (LAR) was performed using a panel of antibodies
according to Lehmann et al. and Turner et al. (3, 5).
For the descriptive analysis, mean (and standard deviation) or
median were used for continuous variables and number and
percentage were used for categorical variables. To enhance
interpretation, stacked bar plots were used to visualize some
categorical variables. Chi square and Fisher’s exact test were used
to test for differences in proportions across subtypes. Overall
survival and disease-free survival were visualized with Kaplan–
Meier plots of survival probability. All analyses were performed in
the R programming language. 
The study was approved by the local ethics committee of Zurich,
Switzerland (BASEC-No. 2017-00219), according to the national
and international ethics guidelines. Informed consent was obtained
from all individual participants included in the study.
Results
We collected data from a total of 166 patients with TNBC.
For the present study, 31 patients had to be excluded due to
the low quality of digital stored images that did not allow a
re-evaluation. The average age of the patients was 58 years
(sd=14) and was similar across the subtypes (Table I). A
higher percentage of postmenopausal women was found in
the LAR subtype. Most patients reported a self-detected
palpable tumor as the reason for first consultation, followed
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Table I. Patient and tumor characteristics.
                                                                                 Overall                     BL                         IM                         ML                           LAR             p-Value
n                                                                                   135                         49                          19                          30                              37                     
Age [y; mean (sd)]                                               57.7 (13.7)            55.3 (14.4)            54.7 (14.4)            57.0 (12.4)               62.9 (12.3)          0.07
Menopausal status (%)                                                                                                                                                                                                 0.02
   Premenopausal                                                     44 (32.6)               20 (40.8)                9 (47.4)                10 (33.3)                    5 (13.5)
   Postmenopausal                                                  91 (67.4)               29 (59.2)               10 (52.6)               20 (66.7)                   32 (86.5)
Reason for first consultation (%)                                                                                                                                                                                 0.39
   Self-detected palpable mass                               80 (59.3)               35 (71.4)               12 (63.2)               18 (60.0)                   15 (40.5)
   Screening                                                            41 (30.4)               10 (20.4)                6 (31.6)                11 (36.7)                   14 (37.8)
   Symptoms (discharge/pain)                                 5 (3.7)                   1 (2.0)                        0                        1 (3.3)                       3 (8.1)
   other                                                                       9 (6.7)                   3 (6.1)                   1 (5.3)                        0                          5 (13.5)
Family history of breast cancer (%)                                                                                                                                                                            0.90
   Yes                                                                       24 (17.8)                9 (18.4)                 4 (21.1)                 6 (20.0)                     5 (13.5)
   No                                                                       110 (81.5)              40 (81.6)               15 (78.9)               24 (80.0)                   31 (83.8)
   Unknown                                                               1 (0.7)                       0                            0                            0                           1 (2.7)
Histopathologic tumor size (%)                                                                                                                                                                                   0.98
   ypT0                                                                       5 (3.7)                   2 (4.1)                   1 (5.3)                   1 (3.3)                       1 (2.7)
   ypT1                                                                     19 (14.1)                6 (12.2)                 5 (26.3)                 4 (13.3)                     4 (10.8)
   ypT2-4                                                                   8 (5.9)                   2 (4.1)                   1 (5.3)                  3 (10.0)                      2 (5.4)
   pT1                                                                       45 (33.3)               16 (32.7)                8 (42.1)                10 (33.3)                   11 (29.7)
   pT2-4                                                                   58 (43.0)               23 (46.9)                4 (21.1)                12 (40.0)                   19 (51.4)
Histopathologic axillary lymph node (%)                                                                                                                                                                   0.44
   ypN0                                                                     13 (9.6)                5 (10.2)                 4 (21.1)                  1 (3.3)                       3 (8.1)
   ypN1-3                                                                 14 (10.4)                 3 (6.1)                  3 (15.8)                 4 (13.3)                     4 (10.8)
   pN0                                                                      77 (57.0)               30 (61.2)               10 (52.6)               19 (63.3)                   18 (48.6)
   pN1-3                                                                   31 (23.0)               11 (22.4)                2 (10.5)                 6 (20.0)                    12 (32.4)
Tumor grading (%)                                                                                                                                                                                                       0.05
   Well differentiated (G1-2)                                  21 (15.6)                 4 (8.2)                  3 (15.8)                 3 (10.0)                    11 (29.7)
   Poor differentiated (G3)                                     114 (84.4)              45 (91.8)               16 (84.2)               27 (90.0)                   26 (70.3)
by findings from a referring physician and findings during
screening at the Breast Center (Table I). Tumor stage did not
vary across subtypes. LAR tumors appeared slightly more
often well differentiated than other subtypes (29.7%; n=11). 
Breast density did not significantly differ within the
subtypes. No tumor was seen upon ultrasound in four patients
(3.0%), while mammography failed to detect 19 cases of
TNBC (14.1%). Benign sonographic classification was given
in 19 cases (14.5%). Most of these showed a horizontal
orientation, hypoechoic pattern, and posterior enhancement
(Table II, Figures 1 and 2). Overall, 66.7% of tumors displayed
a horizontal orientation, 22.2% a vertical orientation, and only
8.1% were round, with little variation across the subtypes. In
mammogram, 35 (26.7%) cases were classified as benign,
mostly due to circumscribed mass without calcification
(11.5%) (Table II and Figure 3). Table II shows the univariate
associations between imaging features and TNBC subtypes. In
ultrasound, BL and IM subtypes were more often spiculated
(61.2% and 68.4%) than ML and LAR (46.7% and 37.8%).
However, the differences were not found to be statistically
significant. Around 80% of tumors exhibited hypoechoic
pattern. A possible relationship between sonographic posterior
pattern and subtype was observed, with less posterior
enhancement in LAR (29.7% versus 56.7-57.9%). 
BL-TNBC presented more often as a mass without
calcification in mammogram than other subtypes (71.4% versus
48.6-57.9%). Mammographic margins of LAR-TNBC were
more often spiculated (24.3% versus 0-4.1% in other subtypes).
Müller et al: Clinical Imaging of TNBC
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Table II. Imaging characteristics in ultrasound and mammogram of distinct TNBC subtypes according to BI-RADS classification. 
                                                                                 Overall                     BL                         IM                         ML                           LAR             p-Value
n                                                                                   135                         49                          19                          30                              37                     
Sonographic shape (%)                                                                                                                                                                                                0.26
   Round/oval                                                            6 (4.4)                   1 (2.0)                  2 (10.0)                  1 (3.3)                       2 (5.4)
   Irregular                                                             125 (92.6)              48 (98.0)               17 (10.5)               27 (90.0)                   33 (89.2)
   No detected tumor                                                 4 (3.0)                       0                            0                        2 (6.7)                       2 (5.4)
Sonographic margin (%)                                                                                                                                                                                              0.11
   Circumscribed                                                      11 (8.1)                  3 (6.1)                  3 (15.8)                  1 (3.3)                      4 (10.8)
   Spiculated                                                            71 (52.6)               30 (61.2)               13 (68.4)               14 (46.7)                   14 (37.6)
   Lobulated                                                             49 (36.3)               16 (32.7)                3 (15.8)                13 (43.3)                   17 (45.9)
   No detected tumor                                                 4 (3.0)                       0                            0                        3 (6.7)                       2 (5.4)
Sonographic pattern (%)                                                                                                                                                                                              0.44
   Complex                                                              21 (15.6)                9 (18.4)                 5 (26.3)                  2 (6.7)                      5 (13.5)
   Hypoechoic                                                         109 (80.7)              39 (79.6)               14 (73.7)               26 (86.7)                   30 (81.1)
   Isoechoic                                                                1 (0.7)                   1 (2.0)                        0                            0                                0
   No detected tumor                                                 4 (3.0)                       0                            0                        2 (6.7)                       2 (5.4)
Sonographic posterior pattern (%)                                                                                                                                                                              0.031
   Posterior enhancement                                        67 (49.6)               28 (57.1)               11 (57.9)               17 (56.1)                   11 (29.7)
   Posterior shadowing                                            34 (25.2)               13 (26.5)                 1 (5.3)                  7 (23.3)                    13 (35.1)
   No change                                                            30 (22.2)                8 (16.3)                 7 (36.8)                 4 (13.3)                    11 (29.7)
   No detected tumor                                                 4 (3.0)                       0                            0                        2 (6.7)                       2 (5.4)
Sonographic orientation                                                                                                                                                                                               0.98
   Horizontal                                                            90 (66.7)               35 (71.4)               13 (68.4)               18 (60.0)                   24 (64.9)
   Vertical                                                                 30 (22.2)               10 (20.4)                4 (21.1)                 7 (23.3)                     9 (24.3)
   Round                                                                    11 (8.1)                  4 (8.2)                  2 (10.5)                 3 (10.0)                      2 (5.4)
   No detected tumor                                                 4 (3.0)                       0                            0                        2 (6.7)                       2 (5.4)
Mammographic shape                                                                                                                                                                                                 0.007
   Focal asymmetry                                                  12 (8.9)                  4 (8.2)                   1 (5.3)                  4 (13.3)                      3 (8.1)
   Mass                                                                     79 (58.5)               35 (71.4)               11 (57.9)               15 (50.0)                   18 (48.6)
   Mass with calcification                                       18 (13.3)                 3 (6.1)                   1 (5.3)                  3 (10.0)                    11 (29.7)
   Calcification only                                                  7 (5.2)                       0                            0                       4 (13.3)                      3 (8.1)
   Distortion                                                                   0                            0                            0                            0                                0
   No detected tumor                                               19 (14.1)                7 (14.3)                 6 (31.6)                 4 (13.3)                      2 (5.4)                  
Mammographic margins                                                                                                                                                                                              0.077
   Circumscribed                                                     51 (37.8)               21 (42.9)                7 (36.8)                11 (36.7)                   12 (32.4)
   Spiculated                                                             12 (8.9)                  2 (4.1)                        0                        1 (3.3)                      9 (24.3)
   Indistinct                                                              46 (34.1)               19 (38.8)                6 (31.6)                10 (33.3)                   11 (29.7)
   Not applicable (no detected                               26 (19.3)                7 (14.3)                 6 (31.6)                 8 (26.7)                     5 (13.5)
   tumor/calcification only)                                           
The relationship of ultrasound and mammogram findings
to initial BI-RADS classification (benign/probably benign
versus probably malignant) is displayed in Figures 1 and 4.
In few cases, BI-RADS classification 1 to 3 was given despite
“typical” malignant patterns such as mass with calcification
in mammogram or irregular shape in ultrasound. 
Discussion
Due to the molecular heterogeneity of TNBC, a marker-
expression based subclassification has been established over
the last few years. Several recent studies have detected
different oncogenic alterations and underline the fact that
ANTICANCER RESEARCH 40: 2125-2131 (2020)
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Figure 1. The relationship of tumor shape in ultrasound to initial BI-RADS classification (benign/probably benign versus probably malignant).
Figure 2. Ultrasound images of BL-TNBC with lobulated margins (A) and IM-TNBC with spiculated margins (B).
TNBC can be further stratified which may lead to a targeted
therapy in TNBC (11). Currently, standard treatment for
TNBC includes chemotherapy. In many cases, neoadjuvant
chemotherapy has the advantages of observing the
responsiveness in-vivo, minimizing the surgical procedure,
and providing an early start to the systemic therapy. As drug
responsiveness differs within the TNBC subtypes, early
subclassification in the neoadjuvant setting can be helpful in
therapeutic decisions (12, 13). Not only pathological
characteristics from a diagnostic biopsy specimen, but also
characteristics such as growth pattern in clinical imaging of
TNBC subtypes will play an important role in identifying the
most promising therapy for every patient. 
TNBC is known to present a benign appearance more
often in mammogram and ultrasound than non-TNBC (7,
14). Due to the heterogeneous pattern of TNBC especially in
ultrasound, some authors have concluded that the predictive
value of sonographic appearance might be low when
comparing TNBC versus non-TNBC (7). However, the
histological subtype heterogeneity of TNBC that may explain
a broad variety of clinical imaging characters has rarely been
considered so far (15, 16). In our study, we compared four
histological subtypes of TNBC: BL, IM, ML, and LAR. This
subtype classification is more and more used in the current
literature; however, data about clinical relevance is still poor
(3, 5, 17). Our study is the first that compares the
radiological features of four TNBC subtypes. 
We observed more often suspicious signs such as
spiculated margins or a mass with calcifications in
mammogram of LAR subtype. These results are in line with
recent studies (18, 19). In these studies, histologic grade
did not differ between LAR-TNBC and control group,
whereas we observed a lower percentage of poorly
differentiated tumors in our group of LAR-TNBC. Lower
histological grading and slower growth can be associated
with a more spiculated, infiltrating growth pattern, giving
the surrounding tissue time for stromal interactions (7).
This may explain our mammographic findings; however,
they seem to be contradictory to the more frequent lobular
sonographic patterns of LAR in our study. In these cases,
it is possible that the tumor was overseen in mammogram
or showed indistinct margins in the correlating
mammogram. Smooth, pushing borders in clinical imaging
as well as in the correlating histopathological microscopic
pictures are typical for highly aggressive tumors (Figure 5).
However, our results imply that not only the grade of
differentiation, but also the histopathological subtype of
TNBC has an impact on its presentation in ultrasound and
mammogram. 
BI-RADS classification provides an established
algorithm to distinguish benign and potential malignant
lesions in the breast. However, daily practice shows a more
complex interaction of clinical presentation, risk factors,
correlation between mammogram and ultrasound, and
individual examiner’s pattern recognition. This may explain
some initial misclassifications by the first examiner of
patients in our study group despite retrospective review of
the images occasionally revealing suspicious signs as
shown in Figures 1 and 4. 
Our study has some limitations to discuss. It is a
retrospective single centre study, and despite the reviewers of
the clinical images being blinded for the histopathological
TNBC subtype, they knew the diagnosis of malignancy. On the
other hand, a review process has the advantage of providing a
more objective evaluation of imaging features. Furthermore, it
allows an interpretation of image characteristics leading to
potential misclassification of malignant tumors. 
The heterogeneous group of TNBC also shows a great
variety of clinical imaging appearance. The authors believe
that the presented analysis, as well as further studies, will
help to provide an early clinical-pathological subtyping of
TNBC prior to a systemic therapy. This is even more
relevant, as developing targeted therapies for TNBC subtypes
is the topic of latest and ongoing clinical trials (20). For
example, if a newly diagnosed TNBC showed spiculated
sonographic margins and mass with calcification in the
mammogram, histopathological subtyping could be indicated
to identify LAR. LAR has a lower pathologic complete
response (pCR) to chemotherapy, which might influence
therapeutic decisions. 
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Figure 3. Mammogram of ML-TNBC with round shape and circumscribed
margin.
Further studies with higher numbers of subtyped TNBC
are warranted to elaborate the impact of histopathological
subtype and tumor differentiation on radiological imaging.
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Figure 5. Microscopic slide (H&E stain) of a surgical specimen of BL-
TNBC that presented benign characteristics in ultrasound. Arrows show
the smooth, “pushing” border of the tumor.
Figure 4. The relationship of tumor shape in mammogram to initial BI-RADS classification (benign/probably benign versus probably malignant).
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